R227
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 114
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.360
- E2F_TARGETS+0.320
- SPERMATOGENESIS+0.320
- G2M_CHECKPOINT+0.260
- KRAS_SIGNALING_DN+0.190
- MYC_TARGETS_V2+0.140
- ANGIOGENESIS+0.120
- KRAS_SIGNALING_UP+0.100
- APICAL_SURFACE+0.090
- INFLAMMATORY_RESPONSE+0.040
Top 10 suppressed
- P53_PATHWAY-0.370
- TNFA_SIGNALING_VIA_NFKB-0.370
- DNA_REPAIR-0.340
- TGF_BETA_SIGNALING-0.340
- WNT_BETA_CATENIN_SIGNALING-0.330
- PI3K_AKT_MTOR_SIGNALING-0.320
- APOPTOSIS-0.310
- NOTCH_SIGNALING-0.300
- UNFOLDED_PROTEIN_RESPONSE-0.300
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.280
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | DRR168608 | — | — | 0.881 |
| 2 | MNG459 | — | — | 0.835 |
| 3 | R283 | — | — | 0.834 |
| 4 | MDT-AP-1141 | Med | Medulloblastoma | 0.834 |
| 5 | MNG159 | — | — | 0.833 |
| 6 | SRR25617835 | — | D | 0.831 |
| 7 | MNG542 | — | — | 0.825 |
| 8 | SRR934973 | — | — | 0.823 |
| 9 | BS_HHPA8NJ2 | medulloblastoma | — | 0.820 |
| 10 | SRR23303770 | — | — | 0.808 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 12 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.360 | Cobimetinib | — uncovered |
| E2F_TARGETS | 0.320 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.320 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.260 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.190 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.140 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.120 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.100 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.090 | Temsirolimus | — uncovered |
| INFLAMMATORY_RESPONSE | 0.040 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.040 | Inavolisib | — uncovered |
| COAGULATION | 0.020 | Binimetinib | — uncovered |